AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Drug Interaction With Metformin
Phase 1
Completed
- Conditions
- Healthy Male and Female Subjects
- Interventions
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2016-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT00546741
- Locations
- 🇺🇸
Bristol-Myers Squibb Clinical Pharmacology Unit, Hamilton, New Jersey, United States
Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT00546520
- Locations
- 🇬🇧
"Altana Pharma/Nycomed", London, United Kingdom
Impact of GERD on Daily Life (NIS)
Completed
- Conditions
- GERD
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2012-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2001
- Registration Number
- NCT00545883
- Locations
- 🇧🇪
Research Site, Zichem, Belgium
A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer
Phase 4
Completed
- Conditions
- Breast Cancer
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2013-01-30
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT00544986
Antibiotic Therapy for Hospital-Acquired Infections in ICU Patients
Completed
- Conditions
- Infection in ICU
- First Posted Date
- 2007-10-15
- Last Posted Date
- 2008-08-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT00543894
Effectiveness of Anti-Psychotic in GPs Setting
Completed
- Conditions
- SchizophreniaBipolar Disorder
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT00543088
- Locations
- 🇧🇪
Research Site, Zonnebeke, Belgium
Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®
Phase 4
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Symbicort Turbuhaler (budesonide/formoterol) 320/9 μgDrug: Seretide Diskus (salmeterol/fluticasone) 50/500 μg
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2012-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 442
- Registration Number
- NCT00542880
- Locations
- 🇬🇧
Research Site, Hamilton, United Kingdom
Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID
Phase 3
Completed
- Conditions
- Gastric UlcerDuodenal UlcerRheumatoid ArthritisOsteoarthritisLumbago
- Interventions
- Drug: PlaceboDrug: Esomeprazole
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2010-05-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 343
- Registration Number
- NCT00542789
- Locations
- 🇯🇵
Research Site, Shizuoka, Japan
Pan-European Survey on the Under Treatment of Hypercholesterolemia
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2007-11-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6500
- Registration Number
- NCT00542867
Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy
Terminated
- Conditions
- Breast Cancer
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1840
- Registration Number
- NCT00542594
© Copyright 2025. All Rights Reserved by MedPath